Dabigatran in secondary stroke prevention: clinical experience with 106 patients.

Biomed Res Int · 2014 · PMC4123474 · PMID 25133166

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

A subgroup analysis in secondary stroke prevention with 3,623 patients showed a nonsignificant trend in favor of dabigatran etexilate having greater efficacy, with a significantly lower rate of CH [ 10 ].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.